1) ARDS is an acute lung condition caused by direct or indirect injury to the lungs. It is characterized by inflammation and fluid buildup in the lungs.
2) The pathophysiology involves activation of the innate immune system and release of cytokines, which damage the alveolar-capillary membrane leading to leakage of fluid into the lungs.
3) Treatment focuses on mechanical ventilation with low tidal volumes, application of PEEP, conservative fluid management, prone positioning in severe cases, and treating the underlying cause.
3. ∗ Review the causes and differentials for ARDS
∗ Briefly discuss the pathophysiology
∗ Discuss the clinical manifestations of ARDS
∗ Understand evidence based treatment options
Objectives
4. ∗ ARDS is also referred with variety of terms like
• Stiff Lung
• Shock lung
• Wet lung
• Post traumatic lung
• Adult respiratory distress syndrome
• Adult hyaline membrane disease
• Capillary leak syndrome &
• Congestive atelectasis.
Acute Respiratory Distress Syndrome
5. June 20, 2012, Vol 307, No. 23
et al. JAMA 2012; 307:2530
-European Society of Intensive Care Medicine with endorsement from
American Thoracic Society and Society of Critical Care Medicine
-Devised three mutually exclusive severity categories: Mild, Moderate
and Severe
-Took into account: timing, chest imaging, origin of edema, oxygenation
7. Bernard et al. AJRCCM 1994; 149:818
Rice et al. Chest 2007: 132: 410
8. ∗ Epidemiology
∗ Annual incidence: 60/100,000
∗ 20% ICU patients meet criteria for ARDS
∗ Morbidity / Mortality
∗ 26-44%, most (80%) deaths attributed to non-pulmonary
organ failure or sepsis
∗ Risk Factors
∗ Advanced age, pre-existing organ dysfunction or chronic medical
illness
∗ Patient with ARDS from direct lung injury has higher incidence of
death than those from non-pulmonary injury
Statistics
Levy BD, & Choi AM, Harrison’s Principles of Internal Medicine, 2012
9. ∗ Direct Lung Injury
∗ Common causes
∗Aspiration of gastric contents or other
substances.
∗Viral/bacterial pneumonia
∗ Less Common causes
∗Chest trauma
∗Embolism: fat, air, amniotic fluid
∗Inhalation of toxic substances
∗Near-drowning
∗O2 toxicity
∗Radiation pneumonitis
ETIOLOGY & RISK FACTORS
10. ∗ Indirect Lung Injury
∗ Common causes
∗ Sepsis
∗ Severe traumatic injury
∗ Less common causes
∗ Acute pancreatitis
∗ Anaphylaxis
∗ Prolonged Cardiopulmonary bypass surgery
∗ Disseminated intravascular coagulation
∗ Multiple blood transfusions
∗ Narcotic drug overdose (e.g., heroin)
∗ Nonpulmonary systemic diseases
∗ Severe head injury
∗ Shock
∗ Massive blood transfusion.
ETIOLOGY & RISK FACTORS
11. ∗ Early signs/symptoms
∗ Restlessness
∗ Dyspnea
∗ Low blood pressure
∗ Confusion
∗ Extreme tiredness
∗ Change in patient’s behavior
∗ Mood swing
∗ Disorientation
∗ Change in LOC
∗ If pneumonia is causing ARDS then client may have
∗ Cough
∗ Fever
CLINICAL MANIFESTATIONS
12. Late signs & symptoms
∗ Severe difficulty in breathing i.e., labored, rapid breathing.
∗ Shortness of breath.
∗ Tachycardia
∗ Cyanosis (blue skin, lips and nails)
∗ Think frothy sputum
∗ Metabolic acidosis
∗ Abnormal breath sounds, like crackles
∗ PaCo2with respiratory alkalosis.
∗ PaO2
CLINICAL MANIFESTATIONS CONTD…………
13. ∗ History of above symptoms
∗ On physical examination
∗ Auscultation reveals abnormal breath sounds
∗ The first tests done are :
∗ Arterial blood gas analysis
∗ Bood tests
∗ Chest x-ray
∗ Sputum cultures and analysis
∗ Other tests are :
∗ Chest CT Scan
∗ Echocardiogram
DIAGNOSITC EVALUATION
14.
15. ∗ Common complications are;
∗ Nosocomial pneumonia:
∗ Barotrauma
∗ Renal failure
∗ Other complications are :
∗ O2 toxicity,
∗ stress ulcers,
∗ Tracheal ulceration,
∗ Blood clots leading to deep vein thrombosis &
∗ pulmonary embolism.
COMPLICATIONS
17. Pathophysiology
1. Direct or indirect injury to
the alveolus causes alveolar
macrophages to release pro-
inflammatory cytokines
Ware et al. NEJM 2000;
342:1334
19. Pathophysiology
3. ACM integrity is lost,
interstitial and alveolus fills with
proteinaceous fluid, surfactant
can no longer support alveolus
Ware et al. NEJM 2000; 342:1334
25. ∗ Fibroproliferative Phase
∗ Variable time period
∗ Fibrosis
∗ Chronic Inflammation
∗ Neovascularisation
∗ Resolution3
∗ Improvement of hypoxaemia
∗ Improved dead space and lung compliance
∗ Resolution radiographic abnormalities
∗ Can take up to 1 year
∗ Residual restrictive or obstructive picture
Post Acute Phase
26. ∗ Chronic Respiratory Disease
∗ Muscle Fatigue
∗ Muscle Wasting
∗ Weakness
Long Term
27. ∗ Treat the underlying cause
∗ Low tidal volume ventilation
∗ Use PEEP
∗ Conservative fluid management
∗ Positioning
∗ Reduce potential complications
Evidence based management of ARDS
28. Hypothesis:
In patients with ALI, ventilation with smaller tidal volumes (6 mL/kg)
will result in better clinical outcomes than traditional tidal volumes (12
mL/kg) ventilation.
ARDS Network N Engl J Med 2000; 342:1301
29. • When compared to larger tidal volumes, Vt of 6ml/kg of ideal
body weight:
• Decreased mortality
• Increased number of ventilator free days
• Decreased extrapulmonary organ failure
• Mortality is decreased in the low tidal volume group despite these
patients having:
• Worse oxygenation
• Increased pCO2 (permissive hypercapnia)
• Lower pH
ARDSnet. NEJM 2000; 342: 1301
Low Tidal Volume Ventilation
30. Low Tidal Volume Ventilation
ARDS affects the lung in a
heterogeneous fashion
• Normal alveoli
• Injured alveoli can
potentially participate in gas
exchange, susceptible to
damage from opening and
closing
• Damaged alveoli filled with
fluid, do not participate in
gas exchange
31. ∗ Protective measure to avoid over distention of
normal alveoli
∗ Uses low (normal) tidal volumes
∗ Minimizes airway pressures
∗ Uses Positive end-expiratory pressure (PEEP)
Low Tidal Volume Ventilation
32. Hypothesis:
In patients with ALI ventilated with 6 mL/kg, higher levels of
PEEP will result in better clinical outcomes than lower levels of
PEEP.
N Engl J Med 2004; 351:327
33. ∗ Higher levels of PEEP/FiO2 does not improve outcomes
∗ may negatively impact outcomes:
∗ Causing increased airway pressure
∗ Increase dead space
∗ Decreased venous return
∗ Barotrauma
PEEP
34. • Positive End Expiratory Pressure
• Every ARDS patient needs it
• Goal is to maximize alveolar recruitment and prevent
cycles of recruitment/derecruitment
PEEP
35. Meade, M et al, JAMA. 2008; 299(6):637-645
-983 patients, randomized into control group with ALI protocol, low Vt and
PEEP vs. Open lung group with low Vt, higher PEEP and recruitment
maneuvers
-No statistically significant difference in mortality outcomes
36. Mercatt, M, et al. JAMA. 2008; 299(6):646-655.
-Multicenter randomized trial, 767 patients. Set a PEEP aimed to increase
alveolar recruitment while limiting hyperinflation
-Randomly assigned two groups: moderate PEEP (5-9cm H2O) vs. level of
PEEP to reach a plateau pressure of 28-30cm H2O
-Found that it didn’t significantly reduce mortality; however, it did improve lung
function and decreased days on vent and organ failure duration
37. ∗ As FiO2 increases, PEEP should also increase
PEEP
ARDSnet. NEJM 2004; 351,
38. ∗ Plateau pressure is most predictive of lung injury
∗ Goal plateau pressure < 30, the lower the better
• Decreases alveolar over-distention and reduces risk of
lung strain
∗ Adjust tidal volume to ensure plateau pressure at goal
∗ It may be permissible to have plateau pressure > 30 in
some cases
• Obesity
• Pregnancy
• Ascites
Airway Pressures in ARDS
Terragni et al. Am J Resp Crit Care Med. 2007;
175(2):160
39. ∗ Assess cause of high Plateau Pressures
∗ Always represents some pathology:
∗ Stiff, non-compliant lung: ARDS, heart failure
∗ Pneumothorax
∗ Auto-peeping
∗ Mucus Plug
∗ Right main stem intubation
∗ Compartment syndrome
∗ Chest wall fat / Obesity
Permissible Plateau Pressures
41. N Engl J Med 2006; 354: 2213
Fluid and Catheter Treatment Trial
--No need for routine PAC use is ALI patients
--Support use of conservative strategy fluid management in patients
with ALI
42. ∗ Using the data from a PAC compared to that from a CVC in
an explicit protocol:
∗ Did not alter survival.
∗ Did not improve organ function.
∗ Did not change outcomes for patients entering in shock
compared to those without shock.
∗ PAC use resulted in more non-fatal complications, mostly
arrhythmias.
Results
N Engl J Med 2006; 354: 2213
43. N Engl J Med. 2006;354:2564
~Hypothesis: Diuresis or fluid restriction may improve lung function but
could jeopardize extrapulmonary organ perfusion
~Conclusion: Conservative fluid management improved lung function and
shortened mechanical ventilation times and ICU days without increasing
nonpulmonary organ failures
44. Fluid Management
• Increased lung water is the
underlying cause of many of
the clinical abnormalities in
ARDS (decreased compliance,
poor gas exchange,
atelectasis)
• After resolution of shock, effort
should be made to attempt
diuresis
• CVP used as guide, goal <4
• Shortens time on vent and ICU
length of stay (13 days vs 11
days)
ARDSnet. NEJM 2006; 354: 2564
45. Hypothesis: Early application of prone positioning would
improve survival in patients with severe ARDS.
Conclusion: Early application of prolonged prone positioning
significantly decreased 28 day and 90 mortality in patients with
severe ARDS.
Guerin et al. NEJM. 2013; 368:2159
46. ∗ Prone positioning
∗ Redistribution of blood & ventilation to least affected areas
of lung
∗ Secretion clearance
∗ Shifts mediastinum anteriorly – assists recruitment of
atelectatic areas
∗ ? reduce lung injury
∗ Reduced lung compression by abdominal contents
Positioning
47. Supine Ventilation
∗ ± 40% lung volume under lung, especially patients
with large hearts
50. ∗ Daily CPAP breathing trial
∗ FiO2 <.40 and PEEP <8
∗ Patient has acceptable spontaneous breathing efforts
∗ No vasopressor requirements, use judgement
∗ Pressure support weaning
∗ PEEP 5, PS at 5cm H2O if RR <25
∗ If not tolerated, RR, Vt – return to A/C↑ ↓
∗ Unassisted breathing
∗ T-piece, trach collar
∗ Assess for 30minutes-2 hours
Weaning
52. 1) Calculate patient’s predicted body weight:
• Men (kg) = 50 + 2.3(height in inches – 60)
• Females (kg) = 45.5 + 2.3(height in inches – 60)
2) Set Vt = predicted body weight x 6cc
3) Set initial rate to approximate baseline minute
ventilation (RR x Vt)
4) Set FiO2 and PEEP to obtain SaO2 goal of >=88%
5) Diurese after resolution of shock
6) Refer to ARDSnet guidelines
Putting it all together
54. ∗ Mechanical Trouble (tubing, ventilator, ptx, plugging)
∗ Neuromuscular blockade
∗ Recruitment maneuvers – positioning, “good lung down”
optimizes V/Q mismatch
∗ Increase PEEP
∗ Inhaled epoprostenol sodium (Flolan)
∗ When inhaled, the vasodilator reaches the normal lung, is
concentrated in normal lung segments and recruits blood flow to
functional alveoli where it is oxygenated. This decreases shunting
and hypoxemia
∗ High frequency ventilation
Refractory Hypoxia
55. Papazian, L, et al. NEJM 2010; 363: 1107-1116.
-Neuromuscular blocking agents may increase oxygenation and decrease
ventilator associated lung injury in severe ARDS patients
-Multicenter double blind trial with 340 patients; received 48hrs of
cisatracurium (Nimbex) or placebo
-Found that early administration of NBA improved 90 day survival and
increased time off vent without increase in muscle weakness
56. ∗ Treat underlying infection
∗ DVT prophylaxis / stress ulcer prevention
∗ Hand washing
∗ Use full barriers with chlorhexadine
∗ Sedation / analgesia
∗ Feeding protocol
∗ Avoid contrast nephropathy
∗ Pressure ulcer prevention, turning Q2h
∗ Avoid steroid use
Supportive Therapies
57. ~No benefit of corticosteroids on survival
~When initiated 2 weeks after onset of ARDS, associated with significant
increase in mortality rate compared to placebo group
N Engl J Med. 2006; 354:1671
58. ∗ Recovery dependent on health prior to onset
∗ Within 6 months, will have reached max recovery
∗ At 1 year post-extubation, >1/3 have normal
spirometry
• Significant burden of emotional and depressive
symptoms with increased depression in ARDS
survivors
∗ Survivor clinic catches symptoms early by screening patients
∗ New treatment modalities, lung protective ventilation
Conclusion
Levy BD, & Choi AM, Harrison’s Principles of Internal Medicine, 2012
Editor's Notes
Non-cardiogenic pulmonary edema
Profound hypoxemia – difference between ali and ards.